Articles tagged with 'Export-IR' | Bayer

Issuance consisted of three tranches with maturities between 3.25 and 10 years and was substantially oversubscribed

The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries / Asundexian is being evaluated as a potential improved treatment option in st...

Group sales stable at 14.389 billion euros (Fx & portfolio adj. minus 1.1 percent)o   Accelerated normalization in glyphosate business – good price dynamics in other Crop Science unitso   New Pharmaceuticals products deliver strong growth – headwinds...

Generating 1,400 GWh annually, Idaho Renewable Energy Agreement Underscores Bayer's Global Commitment to Sustainability and Rural Communities

Substantial sales and earnings growth in 2022 / Dividend of 2.40 euros per share proposed – up 20 percent / Baumann to retire at the end of May – Bill Anderson designated as his successor

Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline / Fifth major cl...

Holistic approach to improve water use and quality across the entire value chain and contribute to an impactful change / Integration of water stewardship in business and investment decisions / Shaping a water-resilient agriculture system with key con...

Nubeqa™ now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer / Additional indication based on data from the pivotal Phase III ARASENS trial ...

Ready-to-use AgPowered Services from Bayer running on the new Microsoft Azure Data Manager for Agriculture / Readymade capabilities and robust digital infrastructure allow innovators to focus on differentiated value / Companies, farmers and consumers...

European Commission granted approval of Nubeqa™ (darolutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) / Approval is based on Phase III ARASENS trial data...

Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, PUL...

Group sales increase 8.7 percent (Fx & portfolio adj.) to 50.739 billion euros / EBITDA before special items rises 20.9 percent to 13.513 billion euros, largely driven by exceptionally strong performance at Crop Science / Pharmaceuticals increases sa...

Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer / New approval based on data from the pivotal Phase III ARASENS trial 

European Commission granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase III FIGARO-DKD cardiovascular (...

Leverkusen, February 8, 2023 – The Supervisory Board of Bayer AG has appointed Bill Anderson to become CEO of Bayer, effective June 1, 2023. He will join Bayer as a member of the Board of Management on April 1, 2023. Bill Anderson was elected unanimo...

Filing for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of clinical trials, PULSAR and PHOTON / In both trials, aflibercept 8 mg demonstrated unprecedented...

Both companies enter into a global strategic partnership for Biologicals discovery and commercialization, that includes crop protection and biostimulant products based on molecules derived from natural sources / Kimitec becomes a new strategic partne...

Biological pheromones present a non-toxic, innovative opportunity for biological crop protection while safeguarding biodiversity and beneficial pollinators / M2i’s patented bio-sourced micro-encapsulation technology means long-lasting pheromone contr...

CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5% compared to ADT with docetaxel alone, with sim...

Oerth’s unique PROTAC® protein degradation technology is expected to be a new, game-changing generation of more sustainable crop protection products / The agreement recommits to the combination of Oerth Bio’s specialized expertise designing PROTAC® d...

Strong market uptake of Nubeqa™ and Kerendia™ / Asundexian projected peak sales of more than five billion euros as treatment option for thrombosis and stroke prevention  / High-value late-stage development portfolio  / Positive study outcomes from ce...

CHMP opinion is based on the results from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), which included approximately 7,400 patients across a broad range of disease...

Bayer receives the highest CDP score for its activities and transparency in climate change / This rating confirms the company’s high commitment to sustainability / A record-breaking 18,700 companies disclosed data on environmental impacts, risks, and...

Recommendation is based on the Phase III study FIREFLEYE and data from the follow-up study FIREFLEYE NEXT / Retinopathy of prematurity (ROP) can lead to severe visual impairment and blindness / Bayer will apply for a patent term extension for the pat...

Group sales increase by 5.7 percent (Fx & portfolio adj.) to 11.281 billion euros  / EBITDA before special items rises by 17.3 percent to 2.451 billion euros / Crop Science achieves strong sales gains – sales also up at Pharmaceuticals and Consumer H...

Study plans to investigate elinzanetant as non-hormonal treatment for vasomotor symptoms caused by endocrine therapy in breast cancer patients  / Elinzanetant is an innovative non-hormonal development compound in development for the treatment of vaso...

Business to continue operations as an independent company called Envu

Aflibercept 8 mg meets primary endpoints in two global pivotal studies in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) achieving non-inferior improvements in best corrected visual acuity to Eylea® (aflibe...

U.S. Food and Drug Administration (FDA) granted label update for Kerendia™ (finerenone) to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) associated with type 2 diabetes...

Succeeds Fei-Fei Li, who stepped down at the end of August